Company intelligence / Profile preview

CaroCure

Stockholm, Sweden

Ownership: Private
Development stage: Other

Overview

CaroCure is a Swedish biotechnology company dedicated to the development of first-in-class small molecule inhibitors for the treatment of cancer. The company's core technology targets the MTH1 enzyme (NUDT1), which cancer cells utilize to sanitize the nucleotide pool and prevent lethal DNA damage from oxidative stress. By inhibiting this "non-oncogene addiction" pathway, CaroCure's candidates selectively induce apoptosis in malignant cells while sparing healthy tissue. The company was founded by Professor Thomas Helleday and is based on research conducted at the Karolinska Institutet. Its lead program, Karonudib, has progressed into early-phase clinical trials for various oncology indications.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Karolinska InstitutetSciLifeLabOxcia

Beyond the preview

Go deeper on CaroCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CaroCure.

Explore the full profile